CDT
CDT Equity Inc.
NASDAQ · USHealthcareBiotechnology
$3.56+13.75%
Price as of Jul 20, 2026
CDT financials
CDT Equity Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $36.8M | $15.4M | $5.3M | $3.2M |
| Operating income | -$36.8M | -$15.4M | -$5.3M | -$3.2M |
| Net income | -$39.2M | -$17.8M | -$535.0K | -$4.9M |
| EBITDA | -$36.5M | -$15.8M | $3.1M | -$4.9M |
| Basic EPS | $-1177.90 | $-61593.00 | $-2397.00 | $-20136.00 |
| Diluted EPS | $-1177.90 | $-61593.00 | $-26760.00 | $-20136.00 |
| Balance sheet | ||||
| Cash & equivalents | $389.9M | $554.0K | $4.2M | $0.00 |
| Total assets | $3.5B | $4.2M | $7.2M | $5.0K |
| Total liabilities | $2.3B | $11.0M | $7.7M | $10.1M |
| Stockholders’ equity | $1.3B | -$6.8M | -$457.0K | -$10.1M |
| Total debt | $1.3B | $7.5M | $985.0K | $2.0M |
| Net debt | $895.8M | $6.9M | -$3.2M | $2.0M |
| Cash flow | ||||
| Operating cash flow | -$15.6M | -$9.7M | -$7.7M | -$2.3M |
| Capital expenditure | -$2.4M | -$51.0K | $0.00 | $0.00 |
| Free cash flow | -$18.0M | -$9.7M | -$7.7M | -$2.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$106.0K | $0.00 | $0.00 | $0.00 |